Apel­lis ris­es on long-term da­ta for Soliris chal­lenger af­ter mixed PhI­II read­out, and an­a­lysts are more bull­ish on ap­proval

Apel­lis Phar­ma­ceu­ti­cals took a beat­ing last Sep­tem­ber af­ter da­ta from two Phase III stud­ies showed con­flict­ing da­ta over whether its eye dis­ease drug worked in a close­ly-watched in­di­ca­tion. But Wednes­day, the biotech fol­lowed up with long-term re­sults that have in­vestors cheer­ing a bit loud­er.

In a cutout of 18-month fol­low-up da­ta, Apel­lis re­vealed its drug pegc­eta­coplan re­mained durable for pa­tients dosed month­ly and once every two months. The re­sults came back sta­tis­ti­cal­ly sig­nif­i­cant in both stud­ies as well, in­clud­ing in the Phase III tri­al that missed 12-month sig­nif­i­cance in Sep­tem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER